Literature DB >> 32144835

Natural history of Ollier disease and Maffucci syndrome: Patient survey and review of clinical literature.

Jad M El Abiad1, Sarah M Robbins2,3, Bernard Cohen4, Adam S Levin1, David L Valle2, Carol D Morris1,5, Nara L de Macena Sobreira2.   

Abstract

Ollier disease (OD) and Maffucci syndrome (MS) are characterized by multiple enchondromas. Patients with MS also have benign vascular overgrowths that become malignant in 8.5% of cases. OD is characterized by multiple enchondromas, typically unilateral in distribution with a predilection for the appendicular skeleton. MS is characterized by multiple enchondromas bilaterally distributed in most of the cases. Both disorders feature multiple swellings on the extremity, deformity around the joints, limitations in joint mobility, scoliosis, bone shortening, leg-length discrepancy, gait disturbances, pain, loss of function, and pathological fractures. About 50% of patients with OD or MS develop a malignancy, such as chondrosarcoma, glioma, and ovarian juvenile granulosa cell tumor. To better understand the natural history of OD and MS, we reviewed 287 papers describing patients with OD and MS. We also created a survey that was distributed directly to 162 patients through Facebook. Here, we compare the review of the cases described in the literature to the survey's responses. The review of the literature showed that: the patients with OD are diagnosed at a younger age; the prevalence of chondrosarcomas among patients with OD or MS was ~30%; in four patients, vascular anomalies were identified in internal organs only; and, the prevalence of cancer among patients with OD or MS was ~50%. With these data, health care providers will better understand the natural history, severity, and prognosis of these diseases and the prevalence of malignancies in these patients. Here, we recommend new guidelines for the care of patients with OD and MS.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Maffucci syndrome; Ollier disease; enchondroma; malignancy; natural history; vascular anomaly

Mesh:

Year:  2020        PMID: 32144835      PMCID: PMC8164175          DOI: 10.1002/ajmg.a.61530

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  21 in total

1.  Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients.

Authors:  Suzan H M Verdegaal; Judith V M G Bovée; Twinkal C Pansuriya; Robert J Grimer; Harzem Ozger; Paul C Jutte; Mikel San Julian; David J Biau; Ingrid C M van der Geest; Andreas Leithner; Arne Streitbürger; Frank M Klenke; Francois G Gouin; Domenico A Campanacci; Perrine Marec-Berard; Pancras C W Hogendoorn; Ronald Brand; Antonie H M Taminiau
Journal:  Oncologist       Date:  2011-12-06

Review 2.  Maffucci's syndrome: functional and neoplastic significance. Case report and review of the literature.

Authors:  R J Lewis; A S Ketcham
Journal:  J Bone Joint Surg Am       Date:  1973-10       Impact factor: 5.284

Review 3.  Ollier Disease: Pathogenesis, Diagnosis, and Management.

Authors:  Avinash Kumar; Vijay Kumar Jain; Minakshi Bharadwaj; Rajendra Kumar Arya
Journal:  Orthopedics       Date:  2015-06       Impact factor: 1.390

4.  Chondrosarcoma in Maffucci's syndrome.

Authors:  T C Sun; R G Swee; T C Shives; K K Unni
Journal:  J Bone Joint Surg Am       Date:  1985-10       Impact factor: 5.284

5.  Bone sarcomas associated with Ollier's disease.

Authors:  J Liu; P G Hudkins; R G Swee; K K Unni
Journal:  Cancer       Date:  1987-04-01       Impact factor: 6.860

6.  PTHR1 mutations associated with Ollier disease result in receptor loss of function.

Authors:  Alain Couvineau; Vinciane Wouters; Guylène Bertrand; Christiane Rouyer; Bénédicte Gérard; Laurence M Boon; Bernard Grandchamp; Miikka Vikkula; Caroline Silve
Journal:  Hum Mol Genet       Date:  2008-06-17       Impact factor: 6.150

Review 7.  Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up.

Authors:  G W Herget; P Strohm; C Rottenburger; U Kontny; T Krauß; J Bohm; N Sudkamp; M Uhl
Journal:  Neoplasma       Date:  2014       Impact factor: 2.575

8.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.

Authors:  M Fernanda Amary; Krisztian Bacsi; Francesca Maggiani; Stephen Damato; Dina Halai; Fitim Berisha; Robin Pollock; Paul O'Donnell; Anita Grigoriadis; Tim Diss; Malihe Eskandarpour; Nadège Presneau; Pancras Cw Hogendoorn; Andrew Futreal; Roberto Tirabosco; Adrienne M Flanagan
Journal:  J Pathol       Date:  2011-05-19       Impact factor: 9.883

Review 9.  Ollier disease.

Authors:  Caroline Silve; Harald Jüppner
Journal:  Orphanet J Rare Dis       Date:  2006-09-22       Impact factor: 4.123

Review 10.  Maffucci syndrome and neoplasms: a case report and review of the literature.

Authors:  Olga Prokopchuk; Stephanie Andres; Karen Becker; Konstantin Holzapfel; Daniel Hartmann; Helmut Friess
Journal:  BMC Res Notes       Date:  2016-02-27
View more
  12 in total

1.  Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report.

Authors:  Haiyan Lv; Hantao Jiang; Minge Zhang; Huarong Luo; Zhenghua Hong; Hai Yang; Weiming Xu; Bo Shen; Wei Zhang; Hao Qiu; Rangteng Zhu
Journal:  World J Surg Oncol       Date:  2022-06-29       Impact factor: 3.253

Review 2.  Cancer Predisposition Syndromes Associated With Pediatric High-Grade Gliomas.

Authors:  Giulia Ceglie; Giada Del Baldo; Emanuele Agolini; Martina Rinelli; Antonella Cacchione; Francesca Del Bufalo; Maria Vinci; Roberto Carta; Luigi Boccuto; Evelina Miele; Angela Mastronuzzi; Franco Locatelli; Andrea Carai
Journal:  Front Pediatr       Date:  2020-11-12       Impact factor: 3.418

Review 3.  Imaging features of cartilaginous tumors of the head and neck.

Authors:  Pattana Wangaryattawanich; Mohit Agarwal; Tanya Rath
Journal:  J Clin Imaging Sci       Date:  2021-12-04

Review 4.  Brain Gliomas and Ollier Disease: Molecular Findings as Predictive Risk Factors?

Authors:  Sergio Corvino; Giuseppe Mariniello; Giuseppe Corazzelli; Raduan Ahmed Franca; Marialaura Del Basso De Caro; Rosa Della Monica; Lorenzo Chiariotti; Francesco Maiuri
Journal:  Cancers (Basel)       Date:  2022-07-16       Impact factor: 6.575

5.  Maffucci syndrome: Case report and review of diagnostic signs of the rare disease.

Authors:  Muhammad Tahir Khan; Sadaf Arooj; Muhammad Umer Mukhtar; Rewati Raman
Journal:  Radiol Case Rep       Date:  2022-08-01

Review 6.  Update on the imaging features of the enchondromatosis syndromes.

Authors:  Ban Sharif; Daniel Lindsay; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2021-07-24       Impact factor: 2.199

Review 7.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

8.  Opportunities and pitfalls of social media research in rare genetic diseases: a systematic review.

Authors:  Emily G Miller; Amanda L Woodward; Grace Flinchum; Jennifer L Young; Holly K Tabor; Meghan C Halley
Journal:  Genet Med       Date:  2021-07-19       Impact factor: 8.864

9.  Somatic IDH1 variant (p.R132C) in an adult male with Maffucci syndrome.

Authors:  Natasha J Brown; Zimeng Ye; Chloe Stutterd; Sureshni I Jayasinghe; Amy Schneider; Saul Mullen; Simone A Mandelstam; Michael S Hildebrand
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

10.  Cell-free DNA from plasma as a promising alternative for detection of gene mutations in patients with Maffucci syndrome.

Authors:  Yi Sun; Xindong Fan; Yamin Rao; Zhenfeng Wang; Deming Wang; Xitao Yang; Lianzhou Zheng; Mingzhe Wen; Ren Cai; Lixin Su
Journal:  Hereditas       Date:  2022-01-18       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.